Targeted Disease(s):
COPD
Purpose of Study:
To evaluate the efficacy of rademikibart compared to placebo as an adjunct to standard therapy on the treatment failure rate within 28 days after randomization in participants with COPD and an eosinophilic phenotype currently experiencing an acute COPD exacerbation.
Study Dates:
August 1, 2025 - May 30, 2026
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Connect Biopharma
Contact:
Clinical Operations
clinical207@connectpharm.com
ClinicalTrails.gov Identifier:
NCT06940154
